Your browser doesn't support javascript.
loading
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi, G N; Stemmer, S M; Burris, H A; Yap, Y S; Sonke, G S; Paluch-Shimon, S; Campone, M; Petrakova, K; Blackwell, K L; Winer, E P; Janni, W; Verma, S; Conte, P; Arteaga, C L; Cameron, D A; Mondal, S; Su, F; Miller, M; Elmeliegy, M; Germa, C; O'Shaughnessy, J.
Affiliation
  • Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: ghortoba@mdanderson.org.
  • Stemmer SM; Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.
  • Burris HA; Sarah Cannon Research Institute, Nashville, USA.
  • Yap YS; Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Sonke GS; Medical Oncology, Netherlands Cancer Institute and BOOG Study Center, Amsterdam, the Netherlands.
  • Paluch-Shimon S; Division of Oncology, Sheba Medical Center, Ramat Gan, Israel.
  • Campone M; Department of Medical Oncology, Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain, France.
  • Petrakova K; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Blackwell KL; Department of Medicine, Duke University Medical Center, Durham.
  • Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Janni W; Department of Gynecology, University of Ulm, Ulm, Germany.
  • Verma S; Department of Oncology, Tom Baker Cancer Centre, Calgary, Canada.
  • Conte P; Department of Surgery, Oncology and Gastroenterology and Division of Medical Oncology; University of Padua and Istituto Oncologico Veneto, IRCCS, Padua, Italy.
  • Arteaga CL; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, USA.
  • Cameron DA; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
  • Mondal S; Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • Su F; Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • Miller M; Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • Elmeliegy M; Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • Germa C; Medical Oncology; Novartis Pharmaceuticals Corporation, East Hanover, USA.
  • O'Shaughnessy J; Texas Oncology-Baylor Charles A. Sammons Cancer Center and The US Oncology Research Network, Dallas, USA.
Ann Oncol ; 29(7): 1541-1547, 2018 07 01.
Article in En | MEDLINE | ID: mdl-29718092
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Biomarkers, Tumor / Liver Neoplasms / Lung Neoplasms / Neoplasm Recurrence, Local Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Biomarkers, Tumor / Liver Neoplasms / Lung Neoplasms / Neoplasm Recurrence, Local Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article